DNA vaccines: An active immunization strategy for prostate cancer Journal Article

  


Authors: Wolchok, J. D.; Gregor, P. D.; Nordquist, L. T.; Slovin, S. F.; Scher, H. I.
Article Title: DNA vaccines: An active immunization strategy for prostate cancer
Abstract: Immunotherapy is currently being investigated as a treatment for patients with asymptomatic, recurrent prostate cancer manifested only by a rising prostate-specific antigen (PSA) level. Several different approaches to active immunization against antigens found on cancer cells have been explored. Immunization with DNA overcomes many of the obstacles noted in previous studies. Injection of plasmid DNA encoding a xenogeneic differentiation antigen (prostate-specific membrane antigen [PSMA]) is a potent means to induce antibody and T-cell responses to these otherwise poorly immunogenic self proteins. Use of the xenogeneic DNA (ie, human PSMA DNA injected into mouse) has been shown to be an absolute requirement to overcome immunologic tolerance. We are currently conducting a phase I trial of human and mouse PSMA DNA vaccines in patients with recurrent prostate cancer, based on preclinical experiments described below. © 2003 Elsevier Inc. All rights reserved.
Keywords: clinical trial; review; nonhuman; t lymphocyte; t-lymphocytes; prostate specific antigen; animals; mice; bcg vaccine; glycoprotein gp 100; cancer immunotherapy; melanoma; neoplasm recurrence, local; dendritic cell; granulocyte macrophage colony stimulating factor; tumor markers, biological; drug evaluation, preclinical; prostate cancer; prostate-specific antigen; prostatic neoplasms; immunological tolerance; dendritic cells; immune tolerance; prostate specific membrane antigen; cancer vaccine; recombinant gamma interferon; cpg island; antibody response; antigen recognition; vaccination; autoantigens; dna vaccine; virus recombinant; disease models, animal; vaccines, dna; glycoprotein; antigen presenting cell; viral vaccines; antigens, tumor-associated, carbohydrate; glutamate carboxypeptidase ii; antigens, surface; keyhole limpet hemocyanin; major histocompatibility antigen class 1; plasmid dna; glycolipid; antigens, heterophile; active immunization; heat-shock proteins; heat shock protein; clinical trials, phase i; humans; human; male; priority journal; 1 fluoro 2,4 dinitrobenzene
Journal Title: Seminars in Oncology
Volume: 30
Issue: 5
ISSN: 0093-7754
Publisher: Elsevier Inc.  
Date Published: 2003-10-01
Start Page: 659
End Page: 666
Language: English
DOI: 10.1016/s0093-7754(03)00356-7
PUBMED: 14571413
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-0142062884&partnerID=40&md5=5028f1079ab622d0468c258bf05fa19d
Notes: Export Date: 25 September 2014 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Luke Nordquist
    4 Nordquist
  2. Susan Slovin
    254 Slovin
  3. Polly Gregor
    29 Gregor
  4. Jedd D Wolchok
    905 Wolchok
  5. Howard Scher
    1130 Scher
Related MSK Work